Compare BW & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | VSTM |
|---|---|---|
| Founded | 1867 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | 2011 |
| Metric | BW | VSTM |
|---|---|---|
| Price | $4.54 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $16.25 | ★ $17.22 |
| AVG Volume (30 Days) | ★ 5.0M | 3.8M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.46 | 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,062,388,000.00 | $30,914,000.00 |
| Revenue This Year | $86.64 | $262.65 |
| Revenue Next Year | $22.38 | $38.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $3.07 | $3.43 |
| 52 Week High | $22.03 | $10.82 |
| Indicator | BW | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 42.54 |
| Support Level | $4.04 | $7.10 |
| Resistance Level | $4.68 | $8.59 |
| Average True Range (ATR) | 0.45 | 0.55 |
| MACD | 0.17 | -0.21 |
| Stochastic Oscillator | 63.15 | 22.53 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.